1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors and immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs), including subgroups with renal impairment (RI) and high-risk (HR) cytogenetics
    Meeting Abstract

    Lonial, S.; Lee, H. C.; Badros, A.; Trudel, S.; Nooka, A. K.; Chari, A.; Abdallah, A. O.; Callander, N. S.; Sborov, D. W.; Suvannasankha, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or an anti-CD38 monoclonal antibody (mAb) - Final primary analysis
    Meeting Abstract

    Richardson, P. G.; Oriol, A.; Larocca, A.; Bladé, J.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • A phase 1b/3 randomized, double-blind, 3-stage study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma
    Meeting Abstract

    Leonard, J.; Batlevi, C. L.; Gabrail, N.; Pagel, J. M.; Yang, J.; Whalen, J.; Adib, D.; Morschhauser, F.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of asciminib in heavily pretreated patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) with sensitivity to tyrosine kinase inhibitors (TKIs)
    Meeting Abstract

    Hughes, T.; Mauro, M.; Kim, D. W.; Cortes, J.; Réa, D.; Minami, H.; Breccia, M.; DeAngelo, D.; Hochhaus, A.; Goh, Y. T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Angioimmunoblastic T-cell lymphoma: Report on 282 cases from the prospective International T-Cell Lymphoma Project
    Meeting Abstract

    Skrypets, T.; Civallero, M.; Manni, M.; Pileri, S.; Weisenburger, D. D.; Ko, Y. H.; Inghirami, G.; Bargetzi, M.; Gabús, R.; Varela, S. B.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Incidence of cardiovascular (CV)-related hospitalizations and associated costs among US patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with first-line (1L) tyrosine kinase inhibitors (TKI) in SIMPLICITY: An observational study
    Meeting Abstract

    Goldberg, S. L.; Mauro, M.; Cortes, J.; Keating, S. J.; Bhandari, H.; Chen, C.
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Interim analysis from the OPTIC trial - A dose-ranging study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J.; Lomaia, E.; Turkina, A.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Rojas, C.; Chuah, C.; Arthur, C.; Apperley, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Retrospective independent review of arterial occlusive events (AOEs) in the ponatinib phase 2 PACE trial (NCT01207440) in patients with Philadelphia chromosome positive (Ph+) leukemia
    Meeting Abstract

    Januzzi, J.; Garasic, J.; Kasner, S.; McDonald, V.; Petrie, M.; Seltzer, J.; Mauro, M.; Croce, K.; Berman, E.; Deininger, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Targeted conditioning with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] leads to high rates of transplantation and engraftment in older patients with active, relapsed, or refractory (rel/ref) AML: Preliminary midpoint results from the prospective, randomized phase 3 SIERRA trial
    Meeting Abstract

    Gyurkocza, B.; Nath, R.; Stiff, P.; Agura, E.; Litzow, M.; Tomlinson, B.; Choe, H.; Abhyankar, S.; Seropian, S.; Chen, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Ivosidenib (IVO) prior to hematopoietic cell transplant (HCT) for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML) who cannot tolerate intensive chemotherapy (IC)
    Meeting Abstract

    DiNardo, C. D.; Stein, E. M.; Pigneux, A.; Altman, J. K.; Collins, R.; Erba, H. P.; Watts, J. M.; Uy, G. L.; Wu, B.; Choe, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save